Skip to main content

3 Reasons to Avoid FTRE and 1 Stock to Buy Instead

FTRE Cover Image

Fortrea has been treading water for the past six months, recording a small loss of 1.7% while holding steady at $9.39.

Is there a buying opportunity in Fortrea, or does it present a risk to your portfolio? Dive into our full research report to see our analyst team’s opinion, it’s free.

Why Do We Think Fortrea Will Underperform?

We don't have much confidence in Fortrea. Here are three reasons why FTRE doesn't excite us and a stock we'd rather own.

1. Revenue Spiraling Downwards

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last four years, Fortrea’s demand was weak and its revenue declined by 2.9% per year. This wasn’t a great result and is a sign of poor business quality.

Fortrea Quarterly Revenue

2. Previous Growth Initiatives Have Lost Money

Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity).

Fortrea’s five-year average ROIC was negative 10.8%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector.

Fortrea Trailing 12-Month Return On Invested Capital

3. New Investments Fail to Bear Fruit as ROIC Declines

ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Over the last few years, Fortrea’s ROIC has unfortunately decreased significantly. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Fortrea Trailing 12-Month Return On Invested Capital

Final Judgment

We cheer for all companies helping people live better, but in the case of Fortrea, we’ll be cheering from the sidelines. That said, the stock currently trades at 12.9× forward P/E (or $9.39 per share). At this valuation, there’s a lot of good news priced in - we think other companies feature superior fundamentals at the moment. We’d suggest looking at one of Charlie Munger’s all-time favorite businesses.

Stocks We Like More Than Fortrea

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.89
+0.00 (0.00%)
AAPL  259.20
+0.00 (0.00%)
AMD  246.83
+0.00 (0.00%)
BAC  53.35
+0.00 (0.00%)
GOOG  319.21
+0.00 (0.00%)
META  634.53
+0.00 (0.00%)
MSFT  384.37
+0.00 (0.00%)
NVDA  189.31
+0.00 (0.00%)
ORCL  155.62
+0.00 (0.00%)
TSLA  352.42
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.